Zenas BioPharma, Inc.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for immune and inflammatory diseases. The company's lead candidate, obexelimab, is a bifunctional monoclonal antibody designed to simultaneously bind CD19 and Fc-gamma-receptor IIb (FcγRIIb) to modulate B cell activation. Obexelimab is being evaluated for multiple indications, including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company's development pipeline also includes ZB002, an anti-TNF-alpha monoclonal antibody; ZB004, a CTLA-4-immunoglobulin fusion protein; and ZB001, an anti-IGF-1R monoclonal antibody targeting oncology applications.

As a clinical-stage entity, Zenas does not currently generate meaningful product revenues. The company operates with approximately 130 full-time employees and is headquartered in Waltham, Massachusetts. Zenas was incorporated in Delaware in 2019, originally established as Zenas BioPharma (Cayman) Limited before reincorporating and changing its name to Zenas BioPharma, Inc. in August 2023. The company is listed on Nasdaq and operates primarily in the United States.